Registry following CPAP use in adults with high blood pressure and sleep apnea
Follows adults with high blood pressure and sleep apnea who use CPAP therapy.
Plain-language title generated from the registry record
Registry title: Prospective National Multi-center Registry of Obstructive Sleep Apnea Syndrome in Hypertensive Patients in China
Key facts
- Where
- Shanghai, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with high blood pressure who are suspected to have obstructive sleep apnea and are on CPAP therapy. It follows how well they keep using CPAP.
- Age
- At least 18 years old.
- Sex
- All sexes can join.
- Disease stage
- High blood pressure with suspected obstructive sleep apnea, confirmed by a hospital sleep study (polysomnography). STOP-Bang questionnaire score of 3 points or more.
- Earlier treatment
- Must be on CPAP therapy now. People treated for sleep apnea without CPAP cannot join.
Main reasons for not taking part
- Clinic blood pressure of 180/110 mmHg or higher
- Severe lung disease such as chronic obstructive pulmonary disease
- Reasons not to use CPAP, such as pneumothorax, pulmonary bulla or a new stroke
- Sleep disorders or insomnia, or not tolerating CPAP
- Cognitive problems that prevent giving informed consent
Read by machine on 12 November 2026.
Where in China
- Shanghai Institite of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of MedicineShanghai, ChinaContact: Jiguang Wang, MD, PhDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Shanghai Jiao Tong University School of Medicine
- Trial code
- NCT05735444
- Record updated
- 21 February 2023
- Original description
Study name: Screening, Diagnosis and Treatment of Obstructive Sleep Apnea Syndrome in Hypertensive Patients in China: A Prospective National Multi-center Registry.Read full original descriptionShow less
Screening, Diagnosis and Treatment of Obstructive Sleep Apnea Syndrome in Hypertensive Patients in China: A Prospective National Multi-center Registry
Study name: Screening, Diagnosis and Treatment of Obstructive Sleep Apnea Syndrome in Hypertensive Patients in China: A Prospective National Multi-center Registry.
Rationale: Obstructive sleep apnoea syndrome (OSAS) is a common secondary cause of hypertension and significantly correlated with the risk of cardiovascular and cerebrovascular diseases. However, continuous positive airway pressure (CPAP) only shows modest blood pressure lowering effect, although it is effective in the relieve of daytime sleepiness and other symptoms of OSAS. One of the possible reasons for the low antihypertensive efficacy might be the low adherence to CPAP therapy. Nonetheless, few studies systematically investigated CPAP adherence with regard to its prediction and clinical relevance for cardiovascular protection and prevention.
Objective: 1) To evaluate short- and long-term CPAP adherence in patients with hypertension and obstructive sleep apnea syndrome; 2) To investigate the predictors of short- and long-term CPAP adherence; 3) To explore the correlation between the CPAP adherence and blood pressure, target organ damage and the incidence of cardiovascular and cerebrovascular events.
Study design: Prospective, multi-center, observational study.
Study population: Patients with hypertension who are suspected to have obstructive sleep apnea syndrome due to snoring, daytime sleepiness and other related symptoms are considered eligible and should meet the following criterias: 1) Agree to participate in the study and sign the informed consent; 2) At least 18 years old; 3) STOP-Bang questionnaire, score ≥3 points; 4) Complete polysomnography in hospital; 5) Currently on CPAP therapy.
Follow up: 3, 6 and 12 months after registry.
Sample size estimation: At least 633 patients.
Timeline: Start of subjects' enrollment: Jan 2023; End of subjects' enrollment: December 2026; End of study: December 2026.
Organization: The Centre for Epidemiological Studies and Clinical Trials, Ruijin Hospital, Shanghai, China.
Inclusion: Agree to participate in the study and sign the informed consent; At least 18 years old; STOP-Bang questionnaire, score ≥3 points; Complete polysomnography in hospital; Currently on CPAP therapy.
Exclusion: Previous or current treatment for OSAS without CPAP; Intolerance of CPAP therapy; Severe respiratory diseases such as chronic obstructive pulmonary disease, or contraindications to CPAP therapy, such as pneumothorax, pulmonary bulla and new-onset stroke；; Sleep disorders or insomnia; Clinic systolic/diastolic blood pressure ≥180/110 mmHg; Patient with cognitive dysfunction who are unable to provide informed consent; Other circumstances that patients are not appropriate for the study upon the investigator's judgment.